NIH National Institute on Aging

‘Dormant’ biotech wakes on Alzheimer’s fast track

By GREGORY ZELLER // A pre-clinical-stage biopharmaceutical company is being fast-tracked toward a potential Alzheimer’s treatment, after taking a decidedly slow road. Stony Brook-based Avanti Biosciences Inc. actually launched in 2009, but was “dormant for a few years,” according to founder Gian Luca Araldi, “kind of an empty shell.” It was only in the last two years, when “I had some ideas I wanted to develop on my own,” that Araldi – a former senior…


ALZ: Genetic variants can run, but they can’t hide

The Feinstein Institute for Medical Research is targeting genetic risk factors behind Alzheimer’s disease, the first of many steps toward new potential treatments. Feinstein Institute assistant professor Yun Freudenberg-Hua has been awarded a five-year, $600,000 grant by the National Institutes of Health’s National Institute on Aging, supporting her mission to better understand the genetic causes of a disease that inflicts an estimated 5.5 million Americans. Ultimately, the doctor and her staff hope to develop new…